SG165322A1 - Engineered anti-il-23 antibodies - Google Patents
Engineered anti-il-23 antibodiesInfo
- Publication number
- SG165322A1 SG165322A1 SG201006284-2A SG2010062842A SG165322A1 SG 165322 A1 SG165322 A1 SG 165322A1 SG 2010062842 A SG2010062842 A SG 2010062842A SG 165322 A1 SG165322 A1 SG 165322A1
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- engineered anti
- engineered
- autoimmune
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71358505P | 2005-08-31 | 2005-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG165322A1 true SG165322A1 (en) | 2010-10-28 |
Family
ID=37685722
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201006284-2A SG165322A1 (en) | 2005-08-31 | 2006-08-29 | Engineered anti-il-23 antibodies |
SG10201402712QA SG10201402712QA (en) | 2005-08-31 | 2006-08-29 | Engineered anti-il-23 antibodies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201402712QA SG10201402712QA (en) | 2005-08-31 | 2006-08-29 | Engineered anti-il-23 antibodies |
Country Status (17)
Country | Link |
---|---|
US (3) | US7807160B2 (fr) |
EP (3) | EP2354160A1 (fr) |
JP (2) | JP5350793B2 (fr) |
CN (1) | CN101296944A (fr) |
CA (1) | CA2620802A1 (fr) |
CY (2) | CY1118760T1 (fr) |
DK (1) | DK1931710T3 (fr) |
ES (1) | ES2619845T3 (fr) |
HR (1) | HRP20170444T1 (fr) |
HU (2) | HUE032131T2 (fr) |
LT (2) | LT1931710T (fr) |
ME (1) | ME02705B (fr) |
PL (1) | PL1931710T3 (fr) |
PT (1) | PT1931710T (fr) |
RS (1) | RS55788B1 (fr) |
SG (2) | SG165322A1 (fr) |
WO (1) | WO2007027714A2 (fr) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3501537A1 (fr) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anticorps anti-il23, compositions, procédés et utilisations |
EP2354160A1 (fr) | 2005-08-31 | 2011-08-10 | Schering Corporation | Synthèse d'anticorps anti-IL-23 |
US20080199460A1 (en) | 2005-09-01 | 2008-08-21 | Schering Corporation | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease |
AU2006342792A1 (en) * | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R |
PL1971366T3 (pl) | 2005-12-29 | 2015-01-30 | Janssen Biotech Inc | Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie |
US7790862B2 (en) * | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
US8414897B1 (en) * | 2006-10-02 | 2013-04-09 | The Uab Research Foundation | Pathway for Th-17 cell development and methods utilizing same |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
SG178804A1 (en) * | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
BRPI0807710B1 (pt) | 2007-02-23 | 2021-12-14 | Merck Sharp & Dohme Corp | Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica |
EP2056838B1 (fr) | 2007-02-28 | 2013-09-25 | Merck Sharp & Dohme Corp. | Polytherapie pour le traitement de troubles immunitaires |
US8119133B2 (en) | 2007-02-28 | 2012-02-21 | Schering Corporation | Engineered anti-IL-23R antibodies |
US7981415B2 (en) * | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
US7771720B2 (en) * | 2007-09-07 | 2010-08-10 | Cisthera, Inc. | Humanized PAI-1 antibodies |
US20100203009A1 (en) * | 2007-10-02 | 2010-08-12 | The Uab Research Foundation | Pathway for Th-17 Cell Development and Methods Utilizing Same |
AR068723A1 (es) * | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
CA3069576A1 (fr) | 2008-01-09 | 2009-07-16 | The Schepens Eye Research Institute, Inc. | Compositions therapeutiques utilisees pour le traitement des affections inflammatoires oculaires |
MX2011001409A (es) | 2008-08-14 | 2011-03-29 | Cephalon Australia Pty Ltd | Anticuerpos anti-il-12/il-23. |
JP5931442B2 (ja) | 2008-08-27 | 2016-06-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 操作された抗IL−23p19抗体の凍結乾燥製剤 |
JP5564049B2 (ja) * | 2008-09-29 | 2014-07-30 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd147抗体、方法及び使用 |
EP2379710A1 (fr) | 2008-12-19 | 2011-10-26 | Schering Corporation | Supplément alimentaire pour culture de cellules de mammifère et procédés d'utilisation |
WO2010127181A1 (fr) * | 2009-04-29 | 2010-11-04 | Trellis Bioscience, Inc. | Anticorps ameliores immunoreactifs avec her3 couple hereguline |
WO2011011797A2 (fr) * | 2009-07-24 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions de cytokine et leurs méthodes dutilisation |
JO3244B1 (ar) * | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
SG177025A1 (en) | 2010-06-21 | 2012-01-30 | Agency Science Tech & Res | Hepatitis b virus specific antibody and uses thereof |
DK3789038T3 (da) * | 2010-05-14 | 2022-10-17 | Univ Leland Stanford Junior | Humaniserede og kimære monoklonale antistoffer mod cd47 |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
CA2805653A1 (fr) | 2010-07-20 | 2012-01-26 | Cephalon Australia Pty Ltd | Anticorps specifiques anti-heterodimere il-23 |
JP6126532B2 (ja) * | 2010-11-04 | 2017-05-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗il−23抗体 |
WO2012112528A1 (fr) * | 2011-02-18 | 2012-08-23 | Merck Sharp & Dohme Corp. | Utilisation d'antagonistes de mdl-1 pour traiter la spondylarthropathie |
EP2583979B1 (fr) | 2011-10-19 | 2015-12-16 | Effimune | Méthodes de preparation d'anticorps dirigés contre la sous-unité p19 de l'IL-23 humaine |
PT2812443T (pt) | 2012-02-06 | 2019-09-05 | Inhibrx Inc | Anticorpos cd47 e métodos de utilização dos mesmos |
MX368653B (es) | 2012-05-03 | 2019-10-10 | Boehringer Ingelheim Int | Anticuerpos anti-il-23p19. |
CN104884473B (zh) | 2012-05-22 | 2019-12-03 | 百时美施贵宝公司 | Il-17a/f il-23双特异性抗体及其应用 |
US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
EP2888283B1 (fr) | 2012-08-24 | 2018-09-19 | The Regents of The University of California | Anticorps et vaccins utilisables en vue du traitement de cancers ror1 et de l'inhibition de la métastase |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
JOP20140049B1 (ar) * | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
NZ712294A (en) | 2013-03-15 | 2020-04-24 | Amgen Inc | Methods for treating crohn’s disease using an anti-il23 antibody |
AU2014238148A1 (en) | 2013-03-15 | 2015-10-08 | Amgen Inc. | Methods for treating psoriasis using an anti-IL-23 antibody |
WO2015031815A2 (fr) | 2013-08-30 | 2015-03-05 | Immunogen, Inc. | Anticorps et dosages pour la détection du récepteur 1 du folate |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
IL307578A (en) * | 2015-02-04 | 2023-12-01 | Boehringer Ingelheim Int | Methods for treating inflammatory diseases |
MX2017013156A (es) | 2015-04-14 | 2018-02-21 | Boehringer Ingelheim Int | Metodos para tratar enfermedades. |
AU2016271857B2 (en) * | 2015-06-03 | 2020-05-28 | Affiris Ag | IL-23-P19 vaccines |
BR112018005175A2 (pt) | 2015-09-17 | 2018-10-16 | Amgen Inc | predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23 |
WO2017049149A1 (fr) | 2015-09-17 | 2017-03-23 | Immunogen, Inc. | Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1 |
TWI733695B (zh) | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
MA43186B1 (fr) * | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
MX2018007589A (es) | 2015-12-22 | 2018-11-09 | Amgen Inc | Ccl20 como indicador de respuesta clinica a antagonistas de il23. |
AU2017250583A1 (en) | 2016-04-15 | 2018-08-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
US10688181B2 (en) | 2016-06-27 | 2020-06-23 | The Regents Of The University Of California | Cancer treatment combinations |
EP3848390A1 (fr) | 2016-10-14 | 2021-07-14 | Boehringer Ingelheim International GmbH | Procédés de traitement de maladies |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3818083A2 (fr) * | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
US20210277105A1 (en) | 2018-07-13 | 2021-09-09 | Astrazeneca Collaboration Ventures, Llc | Treating ulcerative colitis with brazikumab |
JP2021530697A (ja) * | 2018-07-18 | 2021-11-11 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体で治療した後の持続応答予測因子 |
EP3883607A4 (fr) | 2018-11-20 | 2022-08-17 | Janssen Biotech, Inc. | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
CN113874073A (zh) | 2019-05-23 | 2021-12-31 | 詹森生物科技公司 | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 |
CN114466864A (zh) | 2019-06-21 | 2022-05-10 | 索瑞索制药公司 | 多肽 |
CN114514243A (zh) | 2019-06-21 | 2022-05-17 | 索瑞索制药公司 | 多肽 |
GB201911931D0 (en) * | 2019-08-20 | 2019-10-02 | Univ College Cardiff Consultants Ltd | Anti-C7 antibody or antibody fragment |
JP2023509373A (ja) | 2019-12-20 | 2023-03-08 | ノヴァロック バイオセラピューティクス, リミテッド | 抗インターロイキン-23 p19抗体およびそれの使用方法 |
WO2021138409A2 (fr) * | 2019-12-31 | 2021-07-08 | Medstar Health, Inc. | Molécules de liaison anti-cd160 pour traiter des maladies |
CN113698480B (zh) * | 2021-09-18 | 2022-07-01 | 东大生物技术(苏州)有限公司 | 一组il-23单克隆抗体及其医药用途 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0438310A1 (fr) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Méthode de production d'immunoglobulines recombinantes |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
WO1997003715A1 (fr) | 1995-07-21 | 1997-02-06 | The General Hospital Corporation | Procede et appareil permettant de faciliter l'administration d'une preparation pharmaceutique |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
WO1999054357A1 (fr) | 1998-04-14 | 1999-10-28 | Chugai Research Institute For Molecular Medicine, Inc. | Nouvelle proteine du type cytokine |
US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
AU3873200A (en) | 1999-03-11 | 2000-09-28 | Schering Corporation | Mammalian cytokines; related reagents and methods |
ES2300276T5 (es) | 1999-09-09 | 2017-06-02 | Merck Sharp & Dohme Corp. | P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
DK1576011T3 (da) | 2002-10-30 | 2009-11-30 | Genentech Inc | Inhibering af IL-17 produktion |
US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
AU2004219625B9 (en) | 2003-03-10 | 2010-12-23 | Merck Sharp & Dohme Corp. | Uses of IL-23 agonists and antagonists; related reagents |
AU2004239288B2 (en) | 2003-05-09 | 2010-01-28 | Centocor, Inc. | IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
WO2005044853A2 (fr) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anticorps anti-vegf |
DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
PE20090046A1 (es) | 2003-11-10 | 2009-01-26 | Schering Corp | Anticuerpo recombinante humanizado anti-interleuquina 10 |
AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
WO2005120571A2 (fr) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Procede d'immunisation passive contre des maladies ou des troubles caracterise(e)s par agregation amyloide a risque diminue de neuroinflammation |
AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
EP3501537A1 (fr) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anticorps anti-il23, compositions, procédés et utilisations |
WO2007024846A2 (fr) * | 2005-08-25 | 2007-03-01 | Eli Lilly And Company | Anticorps anti-il-23 |
EP2354160A1 (fr) | 2005-08-31 | 2011-08-10 | Schering Corporation | Synthèse d'anticorps anti-IL-23 |
PL1971366T3 (pl) | 2005-12-29 | 2015-01-30 | Janssen Biotech Inc | Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie |
-
2006
- 2006-08-29 EP EP10196318A patent/EP2354160A1/fr not_active Withdrawn
- 2006-08-29 PT PT68025923T patent/PT1931710T/pt unknown
- 2006-08-29 PL PL06802592T patent/PL1931710T3/pl unknown
- 2006-08-29 SG SG201006284-2A patent/SG165322A1/en unknown
- 2006-08-29 SG SG10201402712QA patent/SG10201402712QA/en unknown
- 2006-08-29 RS RS20170285A patent/RS55788B1/sr unknown
- 2006-08-29 DK DK06802592.3T patent/DK1931710T3/en active
- 2006-08-29 ES ES06802592.3T patent/ES2619845T3/es active Active
- 2006-08-29 JP JP2008529203A patent/JP5350793B2/ja not_active Expired - Fee Related
- 2006-08-29 CA CA002620802A patent/CA2620802A1/fr not_active Abandoned
- 2006-08-29 EP EP17151348.4A patent/EP3190125A1/fr not_active Withdrawn
- 2006-08-29 CN CNA2006800401462A patent/CN101296944A/zh active Pending
- 2006-08-29 EP EP06802592.3A patent/EP1931710B1/fr not_active Revoked
- 2006-08-29 ME MEP-2017-73A patent/ME02705B/fr unknown
- 2006-08-29 HU HUE06802592A patent/HUE032131T2/en unknown
- 2006-08-29 WO PCT/US2006/033764 patent/WO2007027714A2/fr active Application Filing
- 2006-08-29 LT LTEP06802592.3T patent/LT1931710T/lt unknown
- 2006-08-29 US US11/511,635 patent/US7807160B2/en active Active
-
2009
- 2009-02-13 US US12/371,157 patent/US8362212B2/en active Active
-
2010
- 2010-09-14 US US12/882,035 patent/US20110002942A1/en not_active Abandoned
-
2011
- 2011-03-24 JP JP2011066727A patent/JP2011130771A/ja active Pending
-
2017
- 2017-03-17 CY CY20171100342T patent/CY1118760T1/el unknown
- 2017-03-20 HR HRP20170444TT patent/HRP20170444T1/hr unknown
-
2019
- 2019-10-24 LT LTPA2019520 patent/LTPA2019520I1/lt unknown
- 2019-10-25 CY CY2019041C patent/CY2019041I2/el unknown
- 2019-10-25 HU HUS1900050 patent/HUS1900050I1/hu unknown
Also Published As
Publication number | Publication date |
---|---|
PL1931710T3 (pl) | 2017-06-30 |
CA2620802A1 (fr) | 2007-03-08 |
CY2019041I1 (el) | 2020-05-29 |
US7807160B2 (en) | 2010-10-05 |
CN101296944A (zh) | 2008-10-29 |
JP2009505677A (ja) | 2009-02-12 |
RS55788B1 (sr) | 2017-08-31 |
EP2354160A1 (fr) | 2011-08-10 |
US20070048315A1 (en) | 2007-03-01 |
US20110002942A1 (en) | 2011-01-06 |
HRP20170444T1 (hr) | 2017-05-19 |
WO2007027714A3 (fr) | 2007-06-21 |
SG10201402712QA (en) | 2014-08-28 |
EP1931710A2 (fr) | 2008-06-18 |
HUE032131T2 (en) | 2017-09-28 |
US20090156788A1 (en) | 2009-06-18 |
PT1931710T (pt) | 2017-03-28 |
CY2019041I2 (el) | 2020-05-29 |
WO2007027714A2 (fr) | 2007-03-08 |
JP5350793B2 (ja) | 2013-11-27 |
EP3190125A1 (fr) | 2017-07-12 |
ME02705B (fr) | 2017-10-20 |
DK1931710T3 (en) | 2017-04-03 |
US8362212B2 (en) | 2013-01-29 |
CY1118760T1 (el) | 2017-07-12 |
EP1931710B1 (fr) | 2017-01-18 |
LTPA2019520I1 (lt) | 2019-11-11 |
ES2619845T3 (es) | 2017-06-27 |
LT1931710T (lt) | 2017-03-27 |
JP2011130771A (ja) | 2011-07-07 |
HUS1900050I1 (hu) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG165322A1 (en) | Engineered anti-il-23 antibodies | |
MX2009009079A (es) | Anticuerpos anti-il-23p19 de ingenieria. | |
MX2009009080A (es) | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. | |
MX2009009283A (es) | Anticuerpos anti-interleuquina -23r de ingenieria. | |
NL301145I1 (fr) | ||
MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
MX2009006471A (es) | Anticuerpo anti especifico de linfopoyetina estromal timica de diseño. | |
IL236427A0 (en) | Human anti-23-il antibodies, preparations, methods and uses | |
MY162511A (en) | Engineered anti-tslp antibody | |
IN2015DN02826A (fr) | ||
GEP201706733B (en) | Anti-il-23 antibodies | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
MX2010008688A (es) | Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. | |
NZ599875A (en) | Human il-23 antigen binding proteins | |
MX2009011500A (es) | Anticuerpos anti-mdl-1. | |
GB0515353D0 (en) | Food | |
SG155947A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1896073A4 (fr) | Anticorps anti-il-23, compositions, méthodes et utilisations | |
TW200728466A (en) | Antibody molecules having specificity for human IL-6 | |
IN2012DN01965A (fr) | ||
MX2010010265A (es) | Metodos para tratar psoriasis. | |
MX2009007570A (es) | Metodos para tratar la psoriasis. |